HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
b0p2dJAQZNHZnU7N